Hypertension Management

1. Hypertension Prevalence and Guideline Emphasis

Hypertension (HTN) affects nearly half of U.S. adults and is the leading modifiable risk factor for cardiovascular disease (CVD), stroke, and kidney failure.[1] As a Family Nurse Practitioner (FNP), you are often the first to diagnose, manage, and monitor HTN in primary care. This study guide focuses on JNC 8 and ACC/AHA 2017 guidelines, which define diagnostic thresholds, treatment targets, and medication selection.[2] Exam questions frequently test guideline cutoffs, drug class indications, and follow-up intervals.

2. Hypertension Subtypes and Organ Involvement

  • Blood pressure (BP): Force of blood against arterial walls, recorded as systolic/diastolic (e.g., 130/80 mm Hg).
  • Primary (essential) HTN: No identifiable cause; accounts for 90–95% of cases. Risk factors include age, obesity, sodium intake, sedentary lifestyle, and family history.[3]
  • Secondary HTN: Caused by an underlying condition (e.g., renal artery stenosis, hyperaldosteronism, sleep apnea, pheochromocytoma). Suspect if onset is abrupt, resistant to therapy, or occurs before age 30.
  • Masked HTN: Normal office BP but elevated ambulatory/home BP.
  • White‑coat HTN: Elevated office BP but normal out‑of‑office readings.
  • Target organ damage (TOD): Subclinical or clinical injury to heart, brain, kidneys, or eyes from chronic HTN (e.g., left ventricular hypertrophy, microalbuminuria, retinopathy).

3. Diagnostic Criteria and BP Targets

3.1 Diagnostic Thresholds (ACC/AHA 2017)[2]

Category Systolic (mm Hg) Diastolic (mm Hg)
Normal <120 and <80
Elevated 120–129 and <80
Stage 1 HTN 130–139 or 80–89
Stage 2 HTN ≥140 or ≥90
Hypertensive Crisis >180 and/or >120

3.2 BP Measurement Best Practices

  1. Patient sits quietly for 5 minutes, feet flat, back supported, arm at heart level.
  2. Use correct cuff size (bladder encircles 80% of arm).
  3. Take 2 readings 1 minute apart; average them. Confirm elevated readings on 2 separate visits before diagnosing.
  4. Ambulatory BP monitoring or home BP monitoring is preferred for confirmation and white‑coat detection.[4]

3.3 Treatment Targets

  • General population: Target BP <130/80 mm Hg.[2]
  • Diabetes or chronic kidney disease (CKD): Same target (<130/80). Older JNC 8 recommended <140/90 for these groups, but ACC/AHA 2017 is now widely adopted for exams.[5]
  • Age ≥65 years: Aim for systolic <130 (if tolerated). Avoid overly aggressive reduction in frail elderly.

4. Common and Severe Clinical Presentations

  • Most patients are asymptomatic until target organ damage occurs.
  • Severe HTN may cause headache (occipital), blurred vision, chest pain, dyspnea, or nosebleeds.
  • Physical exam signs: elevated BP (confirmed), retinopathy (AV nicking, hemorrhages, exudates on fundoscopy), left ventricular heave, fourth heart sound (S4 gallop), abdominal bruit (suggests renal artery stenosis).
  • Look for signs of secondary HTN: truncal obesity/abdominal striae (Cushing’s), diminished femoral pulses (coarctation), tachycardia/sweating (pheochromocytoma).

5. Diagnostic Tests and 10‑Year Risk Estimation

5.1 Initial Diagnostic Tests

  • Basic metabolic panel (BMP) – assess renal function, potassium (hypokalemia suggests hyperaldosteronism).
  • Urinalysis – proteinuria, hematuria (glomerular disease).
  • Lipid panel – risk stratification.
  • Hemoglobin A1c – screen for diabetes.
  • Electrocardiogram (ECG) – evaluate left ventricular hypertrophy, ischemia.
  • Optional: Echocardiogram, renal ultrasound, aldosterone/renin ratio if secondary cause suspected.[3]

5.2 Risk Stratification

  • Estimate 10-year atherosclerotic cardiovascular disease (ASCVD) risk using the ACC/AHA Pooled Cohort Equations.[6]
  • Patients with Stage 1 HTN and ASCVD risk ≥10% should receive both lifestyle modification and pharmacotherapy. If risk <10%, lifestyle alone is appropriate first step.

6. Lifestyle Changes and Medication Algorithms

6.1 Lifestyle Modifications (First-Line for All)

  • Diet: DASH eating plan (dietary approaches to stop hypertension) – rich in fruits, vegetables, low-fat dairy, reduced sodium. Target sodium <2300 mg/day, ideally <1500 mg/day.[7]
  • Weight loss: Maintain BMI 18.5–24.9.
  • Physical activity: ≥150 min/week moderate aerobic activity (e.g., brisk walking).
  • Limit alcohol: Men ≤2 drinks/day, women ≤1 drink/day.

6.2 Pharmacologic Therapy (Stepwise Approach)

  1. First-line agents (nonblack patients): thiazide diuretics (e.g., chlorthalidone, HCTZ), calcium channel blockers (CCBs, e.g., amlodipine), ACE inhibitors (ACEi, e.g., lisinopril), or angiotensin receptor blockers (ARBs, e.g., losartan).[2]
  2. Black patients: First-line is thiazide or CCB alone. ACEi/ARB may be less effective as monotherapy but are still indicated if CKD or proteinuria present.
  3. Stage 2 HTN or BP >20/10 above target: Start two first-line agents (combination therapy, e.g., ACEi + CCB). Consider fixed-dose combinations to improve adherence.
  4. Add-on therapy: If target not reached after about 1 month, add a second agent from another class. Do not combine ACEi with ARB (risk of hyperkalemia/acute kidney injury).
  5. Resistant HTN: BP remains above goal despite ≥3 drugs (including a diuretic). Consider adding mineralocorticoid receptor antagonist (e.g., spironolactone) and referral to specialist.[8]

6.3 Special Populations

  • CKD (with albuminuria): ACEi or ARB are preferred for renoprotection.
  • Diabetes: ACEi or ARB first-line, especially if microalbuminuria present.
  • Pregnancy: Avoid ACEi and ARBs. Preferred agents: methyldopa, labetalol, nifedipine.
  • Heart failure with reduced ejection fraction: Beta-blockers (e.g., metoprolol succinate) + ACEi/ARB + diuretics.

7. Drug Side Effects and Hypertensive Crisis Management

7.1 Drug Side Effects and Warnings

  • ACEi/ARB: Hyperkalemia, cough (ACEi), angioedema, acute kidney injury. Check renal function and potassium 1–2 weeks after initiation.
  • Thiazide diuretics: Hypokalemia, hyponatremia, hyperuricemia, gout. Monitor electrolytes.
  • CCBs: Dihydropyridine (e.g., amlodipine) – peripheral edema, headache; nondihydropyridine (e.g., verapamil) – constipation, bradycardia.
  • Beta-blockers: Bradycardia, fatigue, bronchospasm (avoid in asthma), mask hypoglycemia symptoms.

7.2 Hypertensive Emergency vs. Urgency

  • Emergency: BP >180/120 + acute target organ damage (e.g., encephalopathy, stroke, MI, papilledema). Requires immediate hospital admission and IV therapy (e.g., nitroprusside, nicardipine).
  • Urgency: BP >180/120 without acute TOD. Can be managed with oral agents and close follow-up; do not lower BP too rapidly (risk of hypoperfusion).

7.3 Complications of Untreated HTN

  • Cardiovascular: MI, heart failure, CAD.
  • Cerebrovascular: ischemic and hemorrhagic stroke.
  • Renal: nephrosclerosis, ESRD.
  • Retinopathy: progressive vision loss.
  • Peripheral arterial disease.

8. Memorization Aids and Exam‑Relevant Facts

  • Know that ACC/AHA 2017 defines stage 1 HTN as 130-139/80-89 – this is a common FNP exam question.
  • Memorize first-line drug choices by race and comorbidities (e.g., black patients start on thiazide or CCB; diabetes + CKD = ACEi/ARB).
  • Understand that lifestyle modification is always the initial step for Stage 1 HTN with low ASCVD risk (<10%).
  • On the exam, if a patient with HTN develops new-onset cough, suspect ACEi – switch to ARB.
  • Resistant HTN definition: failure to achieve target on 3 drugs including a diuretic. Add spironolactone.
  • Hypertensive urgency vs. emergency: distinguish by presence of target organ damage (not by BP number alone).
  • Monitor potassium and creatinine 1-2 weeks after starting ACEi/ARB or diuretic.
  • Combination therapy: don’t combine ACEi + ARB (hyperkalemia, AKI).
  • Memory aid: “ABCD” of HTN complications – Aortic dissection, Brain (stroke), Cardiac (MI/HF), kidney (failure).

9. References

  1. Benjamin EJ, Muntner P, Alonso A, et al. Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association. Circulation. 2019;139(10):e56-e528. https://doi.org/10.1161/CIR.0000000000000659
  2. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Hypertension. 2018;71(6):e13-e115. https://doi.org/10.1161/HYP.0000000000000065
  3. Flack JM, Adekola B. Blood pressure and the new ACC/AHA hypertension guidelines. Trends Cardiovasc Med. 2020;30(3):160-164. https://doi.org/10.1016/j.tcm.2019.05.003
  4. Stergiou GS, Palatini P, Parati G, et al. 2021 European Society of Hypertension practice guidelines for office and out-of-office blood pressure measurement. J Hypertens. 2021;39(7):1293-1302. https://doi.org/10.1097/HJH.0000000000002843
  5. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507-520. https://doi.org/10.1001/jama.2013.284427
  6. Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk. Circulation. 2014;129(25 Suppl 2):S49-S73. https://doi.org/10.1161/01.cir.0000437741.48606.98
  7. Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med. 2001;344(1):3-10. https://doi.org/10.1056/NEJM200101043440101
  8. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-3104. https://doi.org/10.1093/eurheartj/ehy339

Ready to test your knowledge?

Master the core responsibilities, scope of practice, and limitations for the Family Nurse Practitioner exam.

Start Practice Questions
Previous Topic Next Topic